| 证券代码 | SCMP.O |
| 证券名称 | Sucampo Pharmaceuticals Inc-A |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2007-08-02 |
| 首发价格(元) | 11.5 USD |
| 首发数量(股) | 3750000 |
| 首发募资额(元) | 43,125,000.00 USD |
| 首发主承销商 | Cowen and Company, LLC |
| 货币单位 | USD |
| 公司名称 | Sucampo Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 805 King Farm Boulevard, Ste 550, Rockville, Maryland, USA |
| 成立日期 | 1996-12 |
| 董事会主席 | Peter S. Greenleaf |
| 公司属地 | United States 美国 |
| 公司网址 | www.sucampo.com |
| 电话 | +1 (301) 961-3400 |
| 传真 | +1 (301) 961-3440 |
| 公司简介 | Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland. |